[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Spyre Therapeutics Inc (SYRE)

Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,815,283
  • Shares Outstanding, K 86,841
  • Annual Sales, $ 0 K
  • Annual Income, $ -155,200 K
  • EBIT $ -202 M
  • EBITDA $ -213 M
  • 60-Month Beta 3.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.66

Options Overview Details

View History
  • Implied Volatility 80.17% (-1.42%)
  • Historical Volatility 57.19%
  • IV Percentile 22%
  • IV Rank 12.43%
  • IV High 222.63% on 09/16/25
  • IV Low 59.96% on 08/18/25
  • Expected Move (DTE 13) 3.40 (4.36%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 9
  • Volume Avg (30-Day) 181
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 2,679
  • Open Int (30-Day) 5,056
  • Expected Range 74.61 to 81.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.70
  • Number of Estimates 6
  • High Estimate $-0.59
  • Low Estimate $-0.80
  • Prior Year $-0.49
  • Growth Rate Est. (year over year) -42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.67 +21.41%
on 05/19/26
79.54 -1.29%
on 06/04/26
+7.50 (+10.57%)
since 05/05/26
3-Month
38.36 +104.68%
on 03/06/26
79.54 -1.29%
on 06/04/26
+37.92 (+93.43%)
since 03/05/26
52-Week
13.93 +463.64%
on 06/17/25
79.54 -1.29%
on 06/04/26
+61.89 (+372.41%)
since 06/05/25

Most Recent Stories

More News
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete Company reiterates expected Q3 2026 readout for rheumatoid arthritis...

SYRE : 78.04 (-0.56%)
Spyre Therapeutics to Participate in Upcoming June Investor Conferences

WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine...

SYRE : 78.04 (-0.56%)
Spyre Therapeutics: Q1 Earnings Snapshot

Spyre Therapeutics: Q1 Earnings Snapshot

SYRE : 78.04 (-0.56%)
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class  ...

SYRE : 78.04 (-0.56%)
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and...

SYRE : 78.04 (-0.56%)
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 78.04 (-0.56%)
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

WALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody...

SYRE : 78.04 (-0.56%)
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody...

SYRE : 78.04 (-0.56%)
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

SPY001 met its primary endpoint with a  statistically significant reduction of 9.2 points (p

SYRE : 78.04 (-0.56%)
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026

WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine...

SYRE : 78.04 (-0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Spyre Therapeutics is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches for patient selection. Spyre Therapeutics, formerly known as Aeglea BioTherapeutics Inc., is based...

See More

Key Turning Points

3rd Resistance Point 87.17
2nd Resistance Point 83.35
1st Resistance Point 80.92
Last Price 78.04
1st Support Level 74.67
2nd Support Level 70.85
3rd Support Level 68.42

See More

52-Week High 79.54
Last Price 78.04
Fibonacci 61.8% 54.48
Fibonacci 50% 46.74
Fibonacci 38.2% 38.99
52-Week Low 13.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.